


CHILDREN'S VACCINE FOR 6 MONTHS TO UNDER 5 YEARS OLD



CLINICAL TRIAL FINDINGS



The clinical trial evaluating the pediatric Moderna Spikevax COVID-19 vaccine took place in Canada and the United States when Omicron was the main variant infecting people. The trial found that for children under 5 years of age the Moderna (25 mcg) 2 dose primary series produced an immune response equaling the response seen in young adults.

The clinical trial also showed that:

- According to preliminary results, the Moderna vaccine prevented symptomatic COVID-19 during Omicron by 50.6% in children 6 to 23 months and 36.8% in children 2 to 5 years.
- There were no deaths or cases of severe COVID-19 or MIS-C among trial participants that received the Moderna vaccine.
- No cases of myocarditis or pericarditis were reported.

Side effects are usually mild and go away within one to three days, such as

Sore arm near the injection site



Feeling tired



Headache



Achy muscles or joints



Fever and chills



SOURCE: [Toronto Public Health](#)



COUNCIL OF
AGENCIES SERVING
SOUTH ASIANS



SOUTH ASIAN
VACCINE
ENGAGEMENT
COLLABORATIVE